Pharmacist Advanced Training Point-of-Care Testing /Test & Treat Written 10h

Now more than ever, pharmacists are at the front line of healthcare delivery, triaging and managing patients with acute and chronic conditions. This 10-hour advanced certificate equips you with the necessary knowledge, skills, and resources to evaluate for, assess, and perform point of care tests in the pharmacy. Don’t miss the opportunity to provide the testing services your patients need.  

Be prepared by taking this course that includes:

  • Pros and cons of testing in the pharmacy
  • Compliance checklist, including how to obtain a CLIA waiver 
  • Procedures for PPE, specimen collecting, and devices to use
  • How to conduct tests for diabetes and hyperlipidemia
  • When and how to administer tests for COVID-19, Influenza, HIV, Hepatitis C, and Group A Strep
  • Documentation of hands-on specimen collection technique, specific to your pharmacy’s operations

Learning Objectives

The course includes 13 lessons. Upon completion of the full course, pharmacists should be able to:
1. Describe current trends in pharmacy practice and point of care testing.
2. List the pros and cons of implementing point of care testing in pharmacy practice.
3. Describe the roles of pharmacy team members in providing point of care testing.
4. Review personal protective equipment (PPE) requirements for various point of care tests.
5. Explain the importance of following point of care testing policies and procedures to mitigate or prevent medication errors.
6. Recall steps for collecting specimens for diagnostic testing.
7. Discuss the epidemiology, signs, symptoms, and diagnostic criteria for various diseases (e.g., Diabetes, Group A Strep, Influenza).
8. Evaluate patient characteristics to identify individuals at risk for various diseases.
9. Compare and contrast the types of point of care tests utilized to test for various diseases.
10. Conduct an appropriate point of care test for an individual who has an indication prompting a disease screening.
11. Interpret the results after conducting a point of care test for various diseases to determine appropriate therapies.
12. Identify patient scenarios where pharmacists may prescribe appropriate therapies.
13. Select appropriate treatment or prevention therapies for eligible patients based on screening, test results, and evidence-based guidelines.
14. Create pharmacy-based interventions (e.g., counseling, monitoring plans, follow-up visits, etc.) for patients living with various diseases.
15. Collaborate interprofessionally with other providers (when appropriate) to achieve optimal patient outcomes.

Faculty

Joshua Davis Kinsey, PharmD

VP, Education
CEimpact

Disclosures:

Joshua Davis Kinsey has no relevant financial relationships with ineligible companies to disclose.

Elizabeth Skoy, PharmD

Professor
North Dakota State University 

Disclosures:

Elizabeth Skoy has no relevant financial relationships with ineligible companies to disclose.

Brett Barker, PharmD

Disclosures:

Brett Barker reports that he is an employee of Nucara. All relevant financial relationships have been mitigated.

Anthony J. Bolus, PharmD, RPh

Disclosures:

Anthony J. Bolus has no relevant financial relationships with ineligible companies to disclose.

Julie Breuer

PharmD Candidate
University of Iowa

Disclosures:

Julie Breuer has no relevant financial relationships with ineligible companies to disclose.

Patrick Devereux, PharmD, RPh

Disclosures:

Patrick Devereux has no relevant financial relationships with ineligible companies to disclose.

Alex Evans, PharmD, MBA

Disclosures:

Alex Evans has no relevant financial relationships with ineligible companies to disclose.

Michele Fountain, PharmD

Disclosures:

Michele Fountain has no relevant financial relationships with ineligible companies to disclose.

John A. Galdo, PharmD, MBA, BCPS, BCGP

Consultant, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad, Inc 

Disclosures:

John Galdo reports that he is CEO of Seguridad and his spouse works for Eli Lilly and was an employee of Prime Therapeutics. All relevant financial relationships have been mitigated.

David Hachey, PharmD, AAHIVP

Disclosures:

David Hachey has no relevant financial relationships with ineligible companies to disclose.

Monica Nikseresht

PharmD Candidate
Drake University

Disclosures:

Monica Nikseresht has no relevant financial relationships with ineligible companies to disclose.

Alexis Page, PharmD

Disclosures:

Alexis Page has no relevant financial relationships with ineligible companies to disclose.

Kathryn Schott, PhD

Vice President - Education Services
CEimpact

Disclosures:

Kathryn Schott has no relevant financial relationships with ineligible companies to disclose.

Beth Cady, PharmD

Disclosures:

Beth Cady has no relevant financial relationships with ineligible companies to disclose.

Course Details